Literature DB >> 1416871

Standardized susceptibility testing of fluconazole: an international collaborative study.

M A Pfaller1, B Dupont, G S Kobayashi, J Müller, M G Rinaldi, A Espinel-Ingroff, S Shadomy, P F Troke, T J Walsh, D W Warnock.   

Abstract

An international collaborative study of broth dilution (MIC) and disk diffusion susceptibility testing of fluconazole was conducted by using a chemically defined medium (High-Resolution Antifungal Assay Medium; Oxoid Ltd., Basingstoke, United Kingdom) and standard test methods performed in eight reference laboratories. Ten yeast isolates were tested by each test method in duplicate on each of 3 separate days. The intralaboratory reproducibility of the MIC test was excellent; 95.7% of the replicate tests (n = 220) were within 2 doubling dilutions of the other values in the set for the eight laboratories. The intralaboratory reproducibility of the disk test was also good, with 91% of the replicate tests (n = 234) agreeing with each other within an arbitrarily chosen value of 4 mm. Interlaboratory agreement of MIC test results was acceptable, with 84% of the MICs agreeing within 2 doubling dilutions. In contrast, the interlaboratory agreement of the disk test was not good, with only 59% of test results agreeing within 4 mm. Comparison of the rank order of MICs obtained in each laboratory with the reference rank order gave an agreement of 70 to 80% (median, 80%) with the MIC test and 70 to 90% (median, 80%) with the disk test. These preliminary results are encouraging for the development of standardized testing methods for testing fluconazole.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1416871      PMCID: PMC192190          DOI: 10.1128/AAC.36.9.1805

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  21 in total

Review 1.  Fluconazole, a new antifungal agent.

Authors:  J N Galgiani
Journal:  Ann Intern Med       Date:  1990-08-01       Impact factor: 25.391

2.  Comparison of relative susceptibilities of Candida species to three antifungal agents as determined by unstandardized methods.

Authors:  J N Galgiani; J Reiser; C Brass; A Espinel-Ingroff; M A Gordon; T M Kerkering
Journal:  Antimicrob Agents Chemother       Date:  1987-09       Impact factor: 5.191

Review 3.  Antifungal susceptibility tests.

Authors:  J N Galgiani
Journal:  Antimicrob Agents Chemother       Date:  1987-12       Impact factor: 5.191

Review 4.  Overview of medically important antifungal azole derivatives.

Authors:  R A Fromtling
Journal:  Clin Microbiol Rev       Date:  1988-04       Impact factor: 26.132

5.  Laboratory evaluation of antifungal agents: a comparative study of five imidazole derivatives of clinical importance.

Authors:  F C Odds
Journal:  J Antimicrob Chemother       Date:  1980-11       Impact factor: 5.790

Review 6.  Treatment of systemic fungal infections: recent progress and current problems.

Authors:  T J Walsh; A Pizzo
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-08       Impact factor: 3.267

7.  Infection control: opportunistic fungal infections--the increasing importance of Candida species.

Authors:  M A Pfaller
Journal:  Infect Control Hosp Epidemiol       Date:  1989-06       Impact factor: 3.254

8.  In vitro sensitivity of Torulopsis glabrata to amphotericin B, 5-fluorocytosine, and clotrimazole (Bay 5097).

Authors:  M I Marks; P Steer; T C Eickhoff
Journal:  Appl Microbiol       Date:  1971-07

9.  Collaborative investigation of variables in susceptibility testing of yeasts.

Authors:  M A Pfaller; M G Rinaldi; J N Galgiani; M S Bartlett; B A Body; A Espinel-Ingroff; R A Fromtling; G S Hall; C E Hughes; F C Odds
Journal:  Antimicrob Agents Chemother       Date:  1990-09       Impact factor: 5.191

10.  Amphotericin B-resistant yeast infection in severely immunocompromised patients.

Authors:  W G Powderly; G S Kobayashi; G P Herzig; G Medoff
Journal:  Am J Med       Date:  1988-05       Impact factor: 4.965

View more
  27 in total

1.  Serotyping of Cryptococcus neoformans strains isolated from clinical specimens in Thailand and their susceptibility to various antifungal agents.

Authors:  N Poonwan; Y Mikami; S Poosuwan; J Boon-Long; N Mekha; M Kusum; K Yazawa; R Tanaka; K Nishimura; K Konyama
Journal:  Eur J Epidemiol       Date:  1997-04       Impact factor: 8.082

2.  Microdilution antifungal susceptibility testing of Candida albicans and Cryptococcus neoformans with and without agitation: an eight-center collaborative study.

Authors:  E J Anaissie; V L Paetznick; L G Ensign; A Espinel-Ingroff; J N Galgiani; C A Hitchcock; M LaRocco; T Patterson; M A Pfaller; J H Rex; M G Rinaldi
Journal:  Antimicrob Agents Chemother       Date:  1996-10       Impact factor: 5.191

Review 3.  Azole resistance in Candida.

Authors:  D W Denning; G G Baily; S V Hood
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-04       Impact factor: 3.267

4.  Correlation between in vitro susceptibility of Candida albicans and fluconazole-resistant oropharyngeal candidiasis in HIV-infected patients.

Authors:  N Troillet; C Durussel; J Bille; M P Glauser; J P Chave
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-12       Impact factor: 3.267

Review 5.  Fluconazole. An update of its antimicrobial activity, pharmacokinetic properties, and therapeutic use in vaginal candidiasis.

Authors:  C M Perry; R Whittington; D McTavish
Journal:  Drugs       Date:  1995-06       Impact factor: 9.546

6.  Susceptibility testing of Candida albicans and Aspergillus species by a simple microtiter menadione-augmented 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide assay.

Authors:  B Jahn; E Martin; A Stueben; S Bhakdi
Journal:  J Clin Microbiol       Date:  1995-03       Impact factor: 5.948

7.  In vitro susceptibility of mycelial and yeast forms of Penicillium marneffei to amphotericin B, fluconazole, 5-fluorocytosine and itraconazole.

Authors:  A S Sekhon; A K Garg; A A Padhye; Z Hamir
Journal:  Eur J Epidemiol       Date:  1993-09       Impact factor: 8.082

8.  Susceptibilities of serial Cryptococcus neoformans isolates from patients with recurrent cryptococcal meningitis to amphotericin B and fluconazole.

Authors:  A Casadevall; E D Spitzer; D Webb; M G Rinaldi
Journal:  Antimicrob Agents Chemother       Date:  1993-06       Impact factor: 5.191

9.  New in vitro assay based on glucose consumption for determining intraconazole and amphotericin B activities against Aspergillus fumigatus.

Authors:  J C Garrigues; G Cadet de Fontenay; M D Linas; M Lagente; J P Seguela
Journal:  Antimicrob Agents Chemother       Date:  1994-12       Impact factor: 5.191

10.  Fluconazole susceptibilities of Candida species and distribution of species recovered from blood cultures over a 5-year period.

Authors:  M F Price; M T LaRocco; L O Gentry
Journal:  Antimicrob Agents Chemother       Date:  1994-06       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.